动态监测上皮性卵巢癌患者术后血清HE4及CA125水平的临床价值  

Clinical value of dynamic monitoring of serum HE4 and CA125 levels in patients with epithelial ovarian cancer

作　　者：范群[1] 李玉芳[1] 范姜铱柔 郭端英[1] 束振华[2] 

机构地区：[1]深圳市龙岗中心医院妇科,广东深圳518116 [2]深圳市龙岗中心医院检验科,广东深圳518116

出　　处：《海南医学》2017年第9期1431-1432,共2页Hainan Medical Journal

基　　金：广东省深圳市龙岗区2012年度科技计划项目(编号:YS2012207)

摘　　要：目的探讨动态监测上皮性卵巢癌患者术后血清人附睾蛋白4(HE4)及糖蛋白抗原125(CA125)水平的临床价值。方法选择2013年3月至2014年10月间我院妇科诊治的72例上皮性卵巢癌患者为研究对象,均接受手术及术后化疗治疗,分别于术前、术后1 d及化疗6周后检测血清HE4及CA125水平,并比较随访两年时存活组和死亡组患者术前血清HE4及CA125水平。结果术前、术后及化疗后6周比较,患者血清HE4、CA125水平分别为(252.56±56.79)pmol/L和(140.54±39.84)U/m L、(166.42±37.78)pmol/L和(76.41±28.56)U/m L、(140.15±30.46)pmol/L和(55.61±16.56)U/m L,均呈明显下降趋势,差异有统计学意义(P<0.05);存活组血清HE4、CA125水平分别为(228.36±52.70)pmol/L和(126.39±31.38)U/m L,均显著低于死亡组的(385.47±60.38)pmol/L和(179.48±29.42)U/m L,差异有统计学意义(P<0.05)。结论血清HE4与CA125是上皮性卵巢的重要血清肿瘤标记物,动态监测血清HE4及CA125水平变化可以辅助判断患者的治疗效果及预后。Objective To investigate the clinical value of dynamic monitoring of serum epididymal protein 4（HE4） and glycoprotein antigen 125（CA125） levels in patients with epithelial ovarian cancer. Methods A total of 72 cases of epithelial ovarian cancer patients, who admitted to Department of Gynecology of our hospital from March 2013 to October 2014, were selected as the research objects. These patients underwent surgery and postoperative chemotherapy, and the serum HE4 and CA125 levels were measured before surgery, one day after surgery and 6 weeks after chemotherapy. The serum HE4 and CA125 levels of the survival group and death group followed up for two years of before surgery were compared. Results Before treatment, 1 day after treatment and 6 weeks after chemotherapy, the serum HE4 and CA125 were（252.56 ± 56.79） pmol/L and（140.54 ± 39.84） U/m L,（166.42 ± 37.78） pmol/L and（76.41 ±28.56） U/m L,（140.15 ± 30.46） pmol/L and（55.61 ± 16.56） U/m L, respectively, which showed a significant downward trend（P〈0.05）. The serum HE4, CA125 levels in survival group were（228.36±52.70） pmol/L and（126.39±31.38） U/m L,which were significantly lower than（385.47±60.38） pmol/L and（179.48±29.42） U/m L in the death group（P〈0.05）. Conclusion The serum HE4 and CA125 are important serum tumor markers in epithelial ovarian, and dynamic monitoring of serum HE4 and CA125 levels can be used to judge the therapeutic effect and prognosis of patients.

关 键 词：上皮性卵巢癌 人附睾蛋白4 糖蛋白抗原125 预后 

分 类 号：R737.31[医药卫生—肿瘤]